Lysophospholipid receptor nomenclature review: IUPHAR Review 8

British Journal of Pharmacology

Volumn 171, Issue 15, 2014, Pages 3575-3594

  Kihara, Yasuyuki ^a   Maceyka, Michael ^b   Spiegel, Sarah ^b   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

FTY720 (fingolimod); G protein coupled receptors; lipid mediators; lysophospholipids; molecular pharamacology

Indexed keywords

GLYCEROPHOSPHOLIPID; LYSOPHOSPHATIDIC ACID 1 RECEPTOR; LYSOPHOSPHATIDIC ACID 2 RECEPTOR; LYSOPHOSPHATIDIC ACID 3 RECEPTOR; LYSOPHOSPHATIDIC ACID 4 RECEPTOR; LYSOPHOSPHATIDIC ACID 5 RECEPTOR; LYSOPHOSPHATIDIC ACID 6 RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDYL INOSITOL 1 RECEPTOR; LYSOPHOSPHATIDYL SERINE 1 RECEPTOR; LYSOPHOSPHATIDYL SERINE 2 RECEPTOR; LYSOPHOSPHATIDYL SERINE 3 RECEPTOR; LYSOPHOSPHOLIPID RECEPTOR; SPHINGOSINE 1 PHOSPHATE 1 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 2 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 3 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 4 RECEPTOR; SPHINGOSINE 1 PHOSPHATE 5 RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; LIGAND;

DEGRADATION; DOWN REGULATION; GENE; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE NOMENCLATURE; GENE SILENCING; HUMAN; INTERNALIZATION; LPAR1 GENE; LPAR2 GENE; LPAR3 GENE; LPAR4 GENE; LPAR5 GENE; LPAR6 GENE; LPIR1 GENE; LYPSR1 GENE; LYPSR2 GENE; LYPSR3 GENE; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; S1PR1 GENE; S1PR2 GENE; S1PR3 GENE; S1PR4 GENE; S1PR5 GENE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; METABOLISM; NOMENCLATURE;

ANIMALS; HUMANS; LIGANDS; RECEPTORS, LYSOPHOSPHOLIPID; TERMINOLOGY AS TOPIC;

EID: 84904600448     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12678     Document Type: Review

References (251)

1. Abbasi T, Garcia JG, (2013). Sphingolipids in lung endothelial biology and regulation of vascular integrity. Handb Exp Pharmacol 216: 201-226.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, etal. (2013a). The concise guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol 170: 1449-1458.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013b). The concise guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013c). The concise guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, etal. (2013d). The concise guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
6. Allard J, Barron S, Diaz J, Lubetzki C, Zalc B, Schwartz JC, etal. (1998). A rat G protein-coupled receptor selectively expressed in myelin-forming cells. Eur J Neurosci 10: 1045-1053.
7. Allende ML, Yamashita T, Proia RL, (2003). G-protein coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102: 3665-3667.
8. Allende ML, Bektas M, Lee BG, Bonifacino E, Kang J, Tuymetova G, etal. (2011). Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem 286: 7348-7358.
9. Amisten S, Braun OO, Bengtsson A, Erlinge D, (2008). Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 122: 47-57.
10. An S, Bleu T, Huang W, Hallmark OG, Coughlin SR, Goetzl EJ, (1997). Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett 417: 279-282.
11. An S, Bleu T, Hallmark OG, Goetzl EJ, (1998). Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 273: 7906-7910.
12. Ansell SM, Akasaka T, McPhail E, Manske M, Braggio E, Price-Troska T, etal. (2012). t(X;14) (p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood 120: 3949-3957.
13. Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, etal. (1999). Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 274: 27776-27785.
14. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K, (2000). Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett 478: 159-165.
15. Bedard A, Tremblay P, Chernomoretz A, Vallieres L, (2007). Identification of genes preferentially expressed by microglia and upregulated during cuprizone-induced inflammation. Glia 55: 777-789.
16. Berchtold S, Ogilvie AL, Bogdan C, Muhl-Zurbes P, Ogilvie A, Schuler G, etal. (1999). Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases. FEBS Lett 458: 424-428.
17. Blaho VA, Hla T, (2011). Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev 111: 6299-6320.
18. Boucher J, Quilliot D, Praderes JP, Simon MF, Gres S, Guigne C, etal. (2005). Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diab Tologia 48: 569-577.
19. Brimacombe M, Ming X, Lamendola M, (2007). Prenatal and birth complications in autism. Matern Child Health J 11: 73-79.
20. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, etal. (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457.
21. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, etal. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 883-897.
22. Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB, (2007). Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 97: 51-59.
23. Calise S, Blescia S, Cencetti F, Bernacchioni C, Donati C, Bruni P, (2012). Sphingosine 1-phosphate stimulates proliferation and migration of satellite cells: role of S1P receptors. Biochim Biophys Acta 1823: 439-450.
24. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, etal. (2009). Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest 119: 1871-1879.
25. Campbell DS, Holt CE, (2001). Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron 32: 1013-1026.
26. Cannon M, Jones PB, Murray RM, (2002). Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 159: 1080-1092.
27. Castilla-Ortega E, Sánchez-Lõpez J, Hoyo-Becerra C, Matas-Rico E, Zambrana-Infantes E, Chun J, etal. (2010). Exploratory, anxiety and spatial memory impairments are dissociated in mice lacking the LPA1 receptor. Neurobiol Learn Mem 94: 73-82.
28. Chan LC, Peters W, Xu Y, Chun J, Farese RV Jr, Cases S, (2007). LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA). J Leukoc Biol 82: 1193-1200.
29. Chen R, Roman J, Guo J, West E, McDyer J, Williams MA, etal. (2006). Lysophosphatidic acid modulates the activation of human monocyte-derived dendritic cells. Stem Cells Dev 15: 797-804.
30. Choi JW, Chun J, (2013). Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta 1831: 20-32.
31. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, etal. (2010). LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186.
32. Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, etal. (2011). FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 108: 751-756.
33. Chun J, Brinkmann V, (2011). A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12: 213-228.
34. Chun J, Hartung HP, (2010). Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33: 91-101.
35. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, etal. (2002). International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54: 265-269.
36. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH, (2010). International union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 62: 579-587.
37. Cohen JA, Chun J, (2011). Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 69: 759-777.
38. Contos JJ, Chun J, (1998). Complete cDNA sequence, genomic structure, and chromosomal localization of the LPA receptor gene, lpA1/vzg-1/Gpcr26. Genomics 51: 364-378.
39. Contos JJ, Chun J, (2000). Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA. Genomics 64: 155-169.
40. Contos JJ, Fukushima N, Weiner JA, Kaushal D, Chun J, (2000a). Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci U S A 97: 13384-13389.
41. Contos JJ, Ishii I, Chun J, (2000b). Lysophosphatidic acid receptors. Mol Pharmacol 58: 1188-1196.
42. Contos JJ, Ye X, Sah VP, Chun J, (2002). Tandem genomic arrangement of a G protein (Gna15) and G protein-coupled receptor (s1p(4)/lp(C1)/Edg6) gene. FEBS Lett 531: 99-102.
43. Cyster JG, Schwab SR, (2012). Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30: 69-94.
44. Danieli-Betto D, Peron S, Germinario E, Zanin M, Sorci G, Franzoso S, etal. (2010). Sphingosine 1-phosphate signaling is involved in skeletal muscle regeneration. Am J Physiol Cell Physiol 298: C550-C558.
45. Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, etal. (2013). International union of basic and clinical pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 65: 967-986.
46. Davis MD, Clemens JJ, Macdonald TL, Lynch KR, (2005). Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 280: 9833-9841.
47. Debien E, Mayol K, Biajoux V, Daussy C, De Aguero MG, Taillardet M, etal. (2013). S1PR5 is pivotal for the homeostasis of patrolling monocytes. Eur J Immunol 43: 1667-1675.
48. Deng W, Balazs L, Wang DA, Van Middlesworth L, Tigyi G, Johnson LR, (2002). Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology 123: 206-216.
49. Estivill-Torrús G, Llebrez-Zayas P, Matas-Rico E, Santín L, Pedraza C, De Diego I, etal. (2008). Absence of LPA1 signaling results in defective cortical development. Cereb Cortex 18: 938-950.
50. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, etal. (2007). Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 31: 441-449.
51. Ferry G, Tellier E, Try A, Gres S, Naime I, Simon MF, etal. (2003). Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278: 18162-18169.
52. Foss FW Jr, Snyder AH, Davis MD, Rouse M, Okusa MD, Lynch KR, etal. (2007). Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem 15: 663-677.
53. Fujita R, Kiguchi N, Ueda H, (2007). LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int 50: 351-355.
54. Fukushima N, Weiner JA, Chun J, (2000). Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev Biol 228: 6-18.
55. Fukushima N, Ishii I, Contos JJ, Weiner JA, Chun J, (2001). Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 41: 507-534.
56. Fukushima N, Weiner JA, Kaushal D, Contos JJ, Rehen SK, Kingsbury MA, etal. (2002). Lysophosphatidic acid influences the morphology and motility of young, postmitotic cortical neurons. Mol Cell Neurosci 20: 271-282.
57. Gaengel K, Niaudet C, Hagikura K, Lavina B, Muhl L, Hofmann JJ, etal. (2012). The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev Cell 23: 587-599.
58. Gardell SE, Dubin AE, Chun J, (2006). Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 12: 65-75.
59. Gilman AG, (1987). G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56: 615-649.
60. Goetzl EJ, Kong Y, Mei B, (1999). Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol 162: 2049-2056.
61. Goetzl EJ, Kong Y, Voice JK, (2000). Cutting edge: differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. J Immunol 164: 4996-4999.
62. Golfier S, Kondo S, Schulze T, Takeuchi T, Vassileva G, Achtman AH, etal. (2010). Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4. FASEB J 24: 4701-4710.
63. Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, Marsolais D, etal. (2008). Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 74: 1308-1318.
64. Gonzalez-Cabrera PJ, Cahalan SM, Nguyen N, Sarkisyan G, Leaf NB, Cameron MD, etal. (2012). S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol Pharmacol 81: 166-174.
65. Graeler M, Goetzl EJ, (2002). Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J 16: 1874-1878.
66. Graler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M, (2003). The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J Cell Biochem 89: 507-519.
67. Green JA, Suzuki K, Cho B, Willison LD, Palmer D, Allen CD, etal. (2011). The sphingosine 1-phosphate receptor S1P(2) maintains the homeostasis of germinal center B cells and promotes niche confinement. Nat Immunol 12: 672-680.
68. Groves A, Kihara Y, Chun J, (2013). Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 328: 9-18.
69. Hama K, Aoki J, Bandoh K, Inoue A, Endo T, Amano T, etal. (2006). Lysophosphatidic receptor, LPA3, is positively and negatively regulated by progesterone and estrogen in the mouse uterus. Life Sci 79: 1736-1740.
70. Hama K, Aoki J, Inoue A, Endo T, Amano T, Motoki R, etal. (2007). Embryo spacing and implantation timing are differentially regulated by LPA3-mediated lysophosphatidic acid signaling in mice. Biol Reprod 77: 954-959.
71. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, Reinhart G, etal. (2012). Crystal structure of a lipid G protein-coupled receptor. Science 335: 851-855.
72. Harris GL, Creason MB, Brulte GB, Herr DR, (2012). In vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody. PLoS ONE 7: e35129.
73. Harrison SM, Reavill C, Brown G, Brown JT, Cluderay JE, Crook B, etal. (2003). LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Mol Cell Neurosci 24: 1170-1179.
74. Heasley BH, Jarosz R, Lynch KR, Macdonald TL, (2004). Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett 14: 2735-2740.
75. Hecht JH, Weiner JA, Post SR, Chun J, (1996). Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 135: 1071-1083.
76. Heise CE, Santos WL, Schreihofer AM, Heasley BH, Mukhin YV, Macdonald TL, etal. (2001). Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 60: 1173-1180.
77. Herr DR, Chun J, (2007). Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 8: 155-167.
78. Herr DR, Grillet N, Schwander M, Rivera R, Muller U, Chun J, (2007). Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. J Neurosci 27: 1474-1478.
79. Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, etal. (2009). LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol 112: 215-223.
80. Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, Goetzl EJ, (2004). Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene 23: 122-129.
81. Hultman CM, SparAcn P, Takei N, Murray RM, Cnattingius S, (1999). Prenatal and perinatal risk factors for schizophrenia, affective psychosis, and reactive psychosis of early onset: case A-control study. BMJ 318: 421-426.
82. Ikeda H, Yatomi Y, Yanase M, Satoh H, Nishihara A, Kawabata M, etal. (1998). Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem Biophys Res Commun 248: 436-440.
83. Im DS, Heise CE, Ancellin N, O'Dowd BF, Shei GJ, Heavens RP, etal. (2000a). Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem 275: 14281-14286.
84. Im DS, Heise CE, Harding MA, George SR, O'Dowd BF, Theodorescu D, etal. (2000b). Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol 57: 753-759.
85. Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, etal. (2012). TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods 9: 1021-1029.
86. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H, (2004). Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 10: 712-718.
87. Inoue M, Ma L, Aoki J, Chun J, Ueda H, (2008a). Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain 4: 6.
88. Inoue M, Ma L, Aoki J, Ueda H, (2008b). Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX-mediated conversion to LPA, an initiator of neuropathic pain. J Neurochem 107: 1556-1565.
89. Ishii I, Contos JJ, Fukushima N, Chun J, (2000). Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol 58: 895-902.
90. Ishii I, Friedman B, Ye X, Kawamura S, McGiffert C, Contos JJ, etal. (2001). Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem 276: 33697-33704.
91. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, etal. (2002). Marked perinatal lethality and cellular signaling deficits in mice Null for the two sphingosine 1-phosphate receptors, S1P2/LPB2/EDG-5 and S1P3/LPB3/EDG-3. J Biol Chem 277: 25152-25159.
92. Ishii I, Fukushima N, Ye X, Chun J, (2004). Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73: 321-354.
93. Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, Vacher J, etal. (2009a). Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458: 524-528.
94. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN, (2010). Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med 207: 2793-2798.
95. Ishii S, Noguchi K, Yanagida K, (2009b). Non-Edg family lysophosphatidic acid (LPA) receptors. Prostaglandins Other Lipid Mediat 89: 57-65.
96. Jacobi FK, Broghammer M, Pesch K, Zrenner E, Berger W, Meindl A, etal. (2000). Physical mapping and exclusion of GPR34 as the causative gene for congenital stationary night blindness type 1. Hum Genet 107: 89-91.
97. Jenne CN, Enders A, Rivera R, Watson SR, Bankovich AJ, Pereira JP, etal. (2009). T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med 206: 2469-2481.
98. Jeong KJ, Park SY, Seo JH, Lee KB, Choi WS, Han JW, etal. (2008). Lysophosphatidic acid receptor 2 and Gi/Src pathway mediate cell motility through cyclooxygenase 2 expression in CAOV-3 ovarian cancer cells. Exp Mol Med 40: 607-616.
99. Jung B, Obinata H, Galvani S, Mendelson K, Ding BS, Skoura A, etal. (2012). Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev Cell 23: 600-610.
100. Kennedy PC, Zhu R, Huang T, Tomsig JL, Mathews TP, David M, etal. (2011). Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther 338: 879-889.
101. Kikuta J, Kawamura S, Okiji F, Shirazaki M, Sakai S, Saito H, etal. (2013). Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci U S A 110: 7009-7013.
102. Kingsbury MA, Rehen SK, Contos JJ, Higgins CM, Chun J, (2003). Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci 6: 1292-1299.
103. Kitamura H, Makide K, Shuto A, Ikubo M, Inoue A, Suzuki K, etal. (2012). GPR34 is a receptor for lysophosphatidylserine with a fatty acid at the sn-2 position. J Biochem 151: 511-518.
104. Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, etal. (2004). Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 6: R640-R646.
105. Kobashi H, Yaoi T, Oda R, Okajima S, Fujiwara H, Kubo T, etal. (2006). Lysophospholipid receptors are differentially expressed in rat terminal Schwann cells, as revealed by a single cell RT-PCR and in situ hybridization. Acta Histochem Cytochem 39: 55-60.
106. Kohno T, Matsuyuki H, Inagaki Y, Igarashi Y, (2003). Sphingosine 1-phosphate promotes cell migration through the activation of Cdc42 in Edg-6/S1P4-expressing cells. Genes Cells 8: 685-697.
107. Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, Yamada T, etal. (2009). LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis 30: 457-465.
108. Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, etal. (2004). The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem 279: 29367-29373.
109. 2 receptor null mice. J Biol Chem 282: 10690-10696.
110. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, etal. (2006). Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 318: 619-628.
111. Kotsikorou E, Lynch DL, Abood ME, Reggio PH, (2011). Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. Chem Phys Lipids 164: 131-143.
112. Kupperman E, An S, Osborne N, Waldron S, Stainier DY, (2000). A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development. Nature 406: 192-195.
113. Lai SL, Yao WL, Tsao KC, Houben AJ, Albers HM, Ovaa H, etal. (2012). Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish. Development 139: 4439-4448.
114. Lai YJ, Chen CS, Lin WC, Lin FT, (2005). c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol Cell Biol 25: 5859-5868.
115. Lai YJ, Lin WC, Lin FT, (2007). PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. J Biol Chem 282: 24381-24387.
116. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K, (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699-2704.
117. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J, (2006). GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281: 23589-23597.
118. Lee CW, Rivera R, Dubin AE, Chun J, (2007). LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem 282: 4310-4317.
119. Lee M, Choi S, Hallden G, Yo SJ, Schichnes D, Aponte GW, (2009). P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion. Am J Physiol Gastrointest Liver Physiol 297: G641-G654.
120. Lee MJ, Thangada S, Liu CH, Thompson BD, Hla T, (1998a). Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J Biol Chem 273: 22105-22112.
121. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, etal. (1998b). Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279: 1552-1555.
122. Lee SJ, Yun CC, (2010). Colorectal cancer cells-proliferation, survival and invasion by lysophosphatidic acid. Int J Biochem Cell Biol 42: 1907-1910.
123. Lee SJ, Ritter SL, Zhang H, Shim H, Hall RA, Yun CC, (2011). MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells. Gastroenterology 140: 924-934.
124. Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, etal. (2008). Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell 19: 5435-5445.
125. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, etal. (2009). Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7: 1064-1077.
126. Liebscher I, Muller U, Teupser D, Engemaier E, Engel KM, Ritscher L, etal. (2011). Altered immune response in mice deficient for the G protein-coupled receptor GPR34. J Biol Chem 286: 2101-2110.
127. Lin FT, Lai YJ, (2008). Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions. Biochim Biophys Acta 1781: 558-562.
128. Lin ME, Rivera RR, Chun J, (2012). Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain. J Biol Chem 287: 17608-17617.
129. Lin S, Yeruva S, He P, Singh AK, Zhang H, Chen M, etal. (2010). Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2. Gastroenterology 138: 649-658.
130. Liu X, Yue S, Li C, Yang L, You H, Li L, (2011). Essential roles of sphingosine 1-phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation. J Cell Physiol 226: 2370-2377.
131. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, etal. (2000). Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951-961.
132. Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA, Billiard J, (2010). LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem 109: 794-800.
133. Loh KC, Leong WI, Carlson ME, Oskouian B, Kumar A, Fyrst H, etal. (2012). Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway. PLoS ONE 7: e37218.
134. Ma L, Uchida H, Nagai J, Inoue M, Chun J, Aoki J, etal. (2009). Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain. Mol Pain 5: 64.
135. Maceyka M, Harikumar KB, Milstien S, Spiegel S, (2012). Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22: 50-60.
136. Maher B, (2012). ENCODE: the human encyclopaedia. Nature 489: 46-48.
137. Makide K, Aoki J, (2013). GPR34 as a lysophosphatidylserine receptor. J Biochem 153: 327-329.
138. Malek RL, Toman RE, Edsall LC, Wong S, Chiu J, Letterle CA, etal. (2001). Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors. J Biol Chem 276: 5692-5699.
139. Manning TJ Jr, Sontheimer H, (1997). Bovine serum albumin and lysophosphatidic acid stimulate calcium mobilization and reversal of cAMP-induced stellation in rat spinal cord astrocytes. Glia 20: 163-172.
140. Masiello LM, Fotos JS, Galileo DS, Karin NJ, (2006). Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells. Bone 39: 72-82.
141. Matas-Rico E, García-Diaz B, Llebrez-Zayas P, Lõpez-Barroso D, Santín L, Pedraza C, etal. (2008). Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Mol Cell Neurosci 39: 342-355.
142. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, etal. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360.
143. Mayol K, Biajoux V, Marvel J, Balabanian K, Walzer T, (2011). Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking. Blood 118: 4863-4871.
144. McGiffert C, Contos JJ, Friedman B, Chun J, (2002). Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis. FEBS Lett 531: 103-108.
145. Mendelson K, Zygmunt T, Torres-Vazquez J, Evans T, Hla T, (2013). Sphingosine 1-phosphate receptor signaling regulates proper embryonic vascular patterning. J Biol Chem 288: 2143-2156.
146. Mohamed OA, Jonnaert M, Labelle-Dumais C, Kuroda K, Clarke HJ, Dufort D, (2005). Uterine Wnt/beta-catenin signaling is required for implantation. Proc Natl Acad Sci U S A 102: 8579-8584.
147. Musazzi L, Di Daniel E, Maycox P, Racagni G, Popoli M, (2010). Abnormalities in alpha/beta-CaMKII and related mechanisms suggest synaptic dysfunction in hippocampus of LPA1 receptor knockout mice. Int J Neuropsychopharmacol 14: 941-953.
148. Mutoh T, Rivera R, Chun J, (2012). Insights into the pharmacological relevance of lysophospholipid receptors. Br J Pharmacol 165: 829-844.
149. Nahum S, Morice-Picard F, Taieb A, Sprecher E, (2011). A novel mutation in LPAR6 causes autosomal recessive hypotrichosis of the scalp. Clin Exp Dermatol 36: 188-194.
150. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, etal. (2008). Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 452: 654-658.
151. Nobusue H, Kondo D, Yamamoto M, Kano K, (2010). Effects of lysophosphatidic acid on the in vitro proliferation and differentiation of a novel porcine preadipocyte cell line. Comp Biochem Physiol B Biochem Mol Biol 157: 401-407.
152. Noguchi K, Chun J, (2011). Roles for lysophospholipid S1P receptors in multiple sclerosis. Crit Rev Biochem Mol Biol 46: 2-10.
153. Noguchi K, Ishii S, Shimizu T, (2003). Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 278: 25600-25606.
154. Noguchi K, Herr D, Mutoh T, Chun J, (2009). Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 9: 15-23.
155. Obo Y, Yamada T, Furukawa M, Hotta M, Honoki K, Fukushima N, etal. (2009). Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat Res/Fundam Mol Mech Mutagen 660: 47-50.
156. Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY, etal. (2008). Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem 283: 21054-21064.
157. Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J, etal. (2012). Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br J Cancer 106: 1453-1459.
158. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, etal. (2003). Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64: 994-1005.
159. Ohuchi H, Hamada A, Matsuda H, Takagi A, Tanaka M, Aoki J, etal. (2008). Expression patterns of the lysophospholipid receptor genes during mouse early development. Dev Dyn 237: 3280-3294.
160. Okabe K, Hayashi M, Fujii M, Honoki K, Mori T, Fukushima N, etal. (2010). Mutations of lysophosphatidic acid receptor genes in human osteosarcoma cells. Pathobiology 77: 278-282.
161. Olivera A, Eisner C, Kitamura Y, Dillahunt S, Allende L, Tuymetova G, etal. (2010). Sphingosine kinase 1 and sphingosine-1-phosphate receptor 2 are vital to recovery from anaphylactic shock in mice. J Clin Invest 120: 1429-1240.
162. Olivera A, Dillahunt SE, Rivera J, (2013). Interrogation of sphingosine-1-phosphate receptor 2 function in vivo reveals a prominent role in the recovery from IgE and IgG-mediated anaphylaxis with minimal effect on its onset. Immunol Lett 150: 89-96.
163. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, etal. (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1
164. Osada M, Yatomi Y, Ohmori T, Ikeda H, Ozaki Y, (2002). Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem Biophys Res Commun 299: 483-487.
165. Ota H, Beutz MA, Ito M, Abe K, Oka M, McMurtry IF, (2011). S1P(4) receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs. Pulm Circ 1: 399-404.
166. Pan S, Mi Y, Pally C, Beerli C, Chen A, Guerini D, etal. (2006). A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 13: 1227-1234.
167. Panchatcharam M, Miriyala S, Yang F, Rojas M, End C, Vallant C, etal. (2008). Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res 103: 662-670.
168. Panther E, Idzko M, Corinti S, Ferrari D, Herouy Y, Mockenhaupt M, etal. (2002). The influence of lysophosphatidic acid on the functions of human dendritic cells. J Immunol 169: 4129-4135.
169. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, etal. (2007). Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316: 295-298.
170. Pasternack SM, von Kugelgen I, Aboud KA, Lee Y-A, Ruschendorf F, Voss K, etal. (2008). G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet 40: 329-334.
171. Pasternack SM, von Kugelgen I, Muller M, Oji V, Traupe H, Sprecher E, etal. (2009). In vitro analysis of LIPH mutations causing hypotrichosis simplex: evidence confirming the role of lipase H and lysophosphatidic acid in hair growth. J Invest Dermatol 129: 2772-2776.
172. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, etal. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
173. Pham TH, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, etal. (2010). Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med 207: 17-27.
174. Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, etal. (2012). Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med 4: 761-775.
175. Pradere JP, Klein J, Gres S, Guigne C, Neau E, Valet P, etal. (2007). LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 18: 3110-3118.
176. Pradere JP, Gonzalez J, Klein J, Valet P, Gres S, Salant D, etal. (2008). Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 1781: 582-587.
177. Qian L, Xu Y, Simper T, Jiang G, Aoki J, Umezu-Goto M, etal. (2006). Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists. Chem Med Chem 1: 376-383.
178. Quancard J, Bollbuck B, Janser P, Angst D, Berst F, Buehlmayer P, etal. (2012). A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol 19: 1142-1151.
179. Rajagopal K, Lefkowitz RJ, Rockman HA, (2005). When 7 transmembrane receptors are not G protein-coupled receptors. J Clin Invest 115: 2971-2974.
180. Rao S, Garrett-Sinha LA, Yoon J, Simon MC, (1999). The Ets factors PU.1 and Spi-B regulate the transcription in vivo of P2Y10, a lymphoid restricted heptahelical receptor. J Biol Chem 274: 34245-34252.
181. Rapizzi E, Donati C, Cencetti F, Nincheri P, Bruni P, (2008). Sphingosine 1-phosphate differentially regulates proliferation of C2C12 reserve cells and myoblasts. Mol Cell Biochem 314: 193-199.
182. Rhee HJ, Nam JS, Sun Y, Kim MJ, Choi HK, Han DH, etal. (2006). Lysophosphatidic acid stimulates cAMP accumulation and cAMP response element-binding protein phosphorylation in immortalized hippocampal progenitor cells. Neuroreport 17: 523-526.
183. Ritscher L, Engemaier E, Staubert C, Liebscher I, Schmidt P, Hermsdorf T, etal. (2012). The ligand specificity of the G-protein-coupled receptor GPR34. Biochem J 443: 841-850.
184. Roberts C, Winter P, Shilliam CS, Hughes ZA, Langmead C, Maycox PR, etal. (2005). Neurochemical changes in LPA1 receptor deficient mice-a putative model of schizophrenia. Neurochem Res 30: 371-377.
185. Rosen H, Stevens RC, Hanson M, Roberts E, Oldstone MB, (2013). Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem 82: 637-662.
186. Rubenfeld J, Guo J, Sookrung N, Chen R, Chaicumpa W, Casolaro V, etal. (2006). Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells. Am J Physiol Lung Cell Mol Physiol 290: L66-L74.
187. Sammani S, Moreno-Vinasco L, Mirzapoiazova T, Singleton PA, Chiang ET, Evenoski CL, etal. (2010). Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am J Respir Cell Mol Biol 43: 394-402.
188. de Sampaio ESTC, Choi JW, Gardell SE, Herr DR, Rehen SK, Gomes FC, etal. (2008). Lysophosphatidic acid receptor-dependent secondary effects via astrocytes promote neuronal differentiation. J Biol Chem 283: 7470-7479.
189. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, etal. (2004). Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279: 13839-13848.
190. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, etal. (2006). Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2: 434-441.
191. Santin LJ, Bilbao A, Pedraza C, Matas-Rico E, Lopez-Barroso D, Castilla-Ortega E, etal. (2009). Behavioral phenotype of maLPA1-null mice: increased anxiety-like behavior and spatial memory deficits. Genes Brain Behav 8: 772-784.
192. Schulze T, Golfier S, Tabeling C, Rabel K, Graler MH, Witzenrath M, etal. (2011). Sphingosine-1-phospate receptor 4 (S1P(4)) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model. FASEB J 25: 4024-4036.
193. Schwab SR, Cyster JG, (2007). Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8: 1295-1301.
194. Shano S, Moriyama R, Chun J, Fukushima N, (2008). Lysophosphatidic acid stimulates astrocyte proliferation through LPA1. Neurochem Int 52: 216-220.
195. Shida D, Kitayama J, Yamaguchi H, Okaji Y, Tsuno NH, Watanabe T, etal. (2003). Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res 63: 1706-1711.
196. Shida D, Fang X, Kordula T, Takabe K, Lepine S, Alvarez SE, etal. (2008). Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 68: 6569-6577.
197. Shimomura Y, Garzon MC, Kristal L, Shapiro L, Christiano AM, (2009). Autosomal recessive woolly hair with hypotrichosis caused by a novel homozygous mutation in the P2RY5 gene. Exp Dermatol 18: 218-221.
198. Shin KJ, Kim YL, Lee S, Kim DK, Ahn C, Chung J, etal. (2009). Lysophosphatidic acid signaling through LPA receptor subtype 1 induces colony scattering of gastrointestinal cancer cells. J Cancer Res Clin Oncol 135: 45-52.
199. Shinkuma S, Akiyama M, Inoue A, Aoki J, Natsuga K, Nomura T, etal. (2010). Prevalent LIPH founder mutations lead to loss of P2Y5 activation ability of PA-PLA1alpha in autosomal recessive hypotrichosis. Hum Mutat 31: 602-610.
200. Shoham AB, Malkinson G, Krief S, Shwartz Y, Ely Y, Ferrara N, etal. (2012). S1P1 inhibits sprouting angiogenesis during vascular development. Development 139: 3859-3869.
201. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, etal. (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7: 539.
202. Simon MF, Daviaud D, Pradere JP, Gres S, Guigne C, Wabitsch M, etal. (2005). Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J Biol Chem 280: 14656-14662.
203. Skipper M, Dhand R, Campbell P, (2012). Presenting ENCODE. Nature 489: 45.
204. Skoura A, Hla T, (2009). Regulation of vascular physiology and pathology by the S1P2 receptor subtype. Cardiovasc Res 82: 221-228.
205. Soliven B, Miron V, Chun J, (2011). The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology 76: S9-S14.
206. Song H, Lim H, Paria BC, Matsumoto H, Swift LL, Morrow J, etal. (2002). Cytosolic phospholipase A2alpha is crucial [correction of A2alpha deficiency is crucial] for 'on-time' embryo implantation that directs subsequent development. Development 129: 2879-2889.
207. Sonoda H, Aoki J, Hiramatsu T, Ishida M, Bandoh K, Nagai Y, etal. (2002). A novel phosphatidic acid-selective phospholipase A1 that produces lysophosphatidic acid. J Biol Chem 277: 34254-34263.
208. Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ, etal. (2003). Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 64: 1199-1209.
209. Spiegel S, Milstien S, (2011). The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 11: 403-415.
210. Spohr TC, Choi JW, Gardell SE, Herr DR, Rehen SK, Gomes FC, etal. (2008). Lysophosphatidic acid receptor-dependent secondary effects via astrocytes promote neuronal differentiation. J Biol Chem 283: 7470-7479.
211. Sugita K, Yamamura C, Tabata K, Fujita N, (2013). Expression of orphan G-protein coupled receptor GPR174 in CHO cells induced morphological changes and proliferation delay via increasing intracellular cAMP. Biochem Biophys Res Commun 430: 190-195.
212. Sugo T, Tachimoto H, Chikatsu T, Murakami Y, Kikukawa Y, Sato S, etal. (2006). Identification of a lysophosphatidylserine receptor on mast cells. Biochem Biophys Res Commun 341: 1078-1087.
213. Suidan HS, Nobes CD, Hall A, Monard D, (1997). Astrocyte spreading in response to thrombin and lysophosphatidic acid is dependent on the Rho GTPase. Glia 21: 244-252.
214. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, etal. (2006). Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 173: 301-310.
215. Sukocheva O, Wadham C, Xia P, (2013). Estrogen defines the dynamics and destination of transactivated EGF receptor in breast cancer cells: role of S1P(3) receptor and Cdc42. Exp Cell Res 319: 455-465.
216. Sumida H, Noguchi K, Kihara Y, Abe M, Yanagida K, Hamano F, etal. (2010). LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood 116: 5060-5070.
217. Sun X, Singleton PA, Letsiou E, Zhao J, Belvitch P, Sammani S, etal. (2012). Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injury. Am J Respir Cell Mol Biol 47: 628-636.
218. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, Prodanovich PC, etal. (2010). A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol 160: 1699-1713.
219. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, etal. (2008). The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14: 45-54.
220. Taghavi P, Verhoeven E, Jacobs JJ, Lambooij JP, Stortelers C, Tanger E, etal. (2008). In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene 27: 6806-6816.
221. Trimbuch T, Beed P, Vogt J, Schuchmann S, Maier N, Kintscher M, etal. (2009). Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signaling. Cell 138: 1222-1235.
222. UniprotConsortium (2013). Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res 41: D43-D47.
223. Valet P, Pages C, Jeanneton O, Daviaud D, Barbe P, Record M, etal. (1998). Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth. J Clin Invest 101: 1431-1438.
224. Van Brocklyn JR, Graler MH, Bernhardt G, Hobson JP, Lipp M, Spiegel S, (2000). Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood 95: 2624-2629.
225. Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, etal. (2007). Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 8: 1337-1344.
226. Wang L, Dudek SM, (2009). Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 77: 39-45.
227. Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, etal. (2007). Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 41: 616-623.
228. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, etal. (2010). High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 177: 2205-2215.
229. Weiner JA, Chun J, (1999). Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc Natl Acad Sci U S A 96: 5233-5238.
230. Weiner JA, Hecht JH, Chun J, (1998). Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain. J Comp Neurol 398: 587-598.
231. Weiner JA, Fukushima N, Contos JJ, Scherer SS, Chun J, (2001). Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci 21: 7069-7078.
232. Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, etal. (2009). Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem 284: 17304-17319.
233. Wu J, Zern MA, (2000). Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 35: 665-672.
234. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, etal. (2004). Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 279: 6595-6605.
235. Yanagida K, Ishii S, Hamano F, Noguchi K, Shimizu T, (2007). LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J Biol Chem 282: 5814-5824.
236. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, etal. (2009). Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 284: 17731-17741.
237. Yanagida K, Kurikawa Y, Shimizu T, Ishii S, (2013). Current progress in non-Edg family LPA receptor research. Biochim Biophys Acta 1831: 33-41.
238. Yang L, Yue S, Liu X, Han Z, Zhang Y, Li L, (2013). Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J Hepatol 59: 114-123.
239. Ye D, Lin F, (2013). S1pr2/Galpha13 signaling controls myocardial migration by regulating endoderm convergence. Development 140: 789-799.
240. Ye X, (2008). Lysophospholipid signaling in the function and pathology of the reproductive system. Hum Reprod Update 14: 519-536.
241. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, etal. (2005). LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435: 104-108.
242. Yu N, Lariosa-Willingham KD, Lin FF, Webb M, Rao TS, (2004). Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45: 17-27.
243. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, etal. (2008). Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100: 1630-1642.
244. Yu W, Ma S, Wang L, Zuo B, Li M, Qiao Z, etal. (2013). Upregulation of GPR34 expression affects the progression and prognosis of human gastric adenocarcinoma by PI3K/PDK1/AKT pathway. Histol Histopathol 28: 1629-1638.
245. Yuan XB, Jin M, Xu X, Song YQ, Wu CP, Poo MM, etal. (2003). Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat Cell Biol 5: 38-45.
246. Yun CC, Sun H, Wang D, Rusovici R, Castleberry A, Hall RA, etal. (2005). LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol 289: C2-C11.
247. Yung Y, Mutoh T, Lin ME, Noguchi K, Rivera RR, Choi JW, etal. (2011). Lysophosphatidic acid signaling may initiate fetal hydrocephalus. Sci Transl Med 3: 99ra87.
248. Zhang G, Contos JJ, Weiner JA, Fukushima N, Chun J, (1999). Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. Gene 227: 89-99.
249. Zhao SX, Xue LQ, Liu W, Gu ZH, Pan CM, Yang SY, etal. (2013). Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis. Hum Mol Genet 22: 3347-3362.
250. Zheng Y, Voice JK, Kong Y, Goetzl EJ, (2000). Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. FASEB J 14: 2387-2389.
251. Zheng Y, Kong Y, Goetzl EJ, (2001). Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 166: 2317-2322.